[Effective therapy in highly active pediatric multiple sclerosis]

Area of Science:

• Pediatric Neurology
• Neuroimmunology
• Demyelinating Diseases

Background:

• Childhood multiple sclerosis (MS) affects individuals under 18, presenting with relapsing-remitting disease.
• Increasing incidence of pediatric MS necessitates advanced treatment strategies.
• Early diagnosis and intervention are crucial for managing pediatric MS and improving quality of life.

Observation:

• Pediatric MS exhibits a high relapse rate and rapid progression.
• First-line disease-modifying therapies (DMTs) show suboptimal response in nearly 45% of cases.
• Natalizumab has shown potential in adult MS but lacked extensive pediatric evidence.

Findings:

• Three pediatric patients with active relapsing-remitting MS were successfully treated with off-label natalizumab.
• This treatment was individually authorized, indicating a need for effective options in this population.
• The successful outcomes suggest natalizumab's potential as a second-line therapy for severe childhood MS.

Implications:

• Off-label natalizumab may be a viable option for active pediatric MS unresponsive to initial DMTs.
• Further evidence-based studies are warranted to confirm natalizumab's efficacy and safety in children.
• This approach highlights the importance of personalized medicine in managing rare pediatric neurological conditions.